Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 18/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10356261 | 0.75 | GRM5 (0.45) | GRM5CNR1 | |
| SCHEMBL30988460 | 0.75 | GRM5 (0.59) | GRM5CNR1 | |
| SCHEMBL14996604 | 0.74 | GRM5 (0.43) | GRM5CNR1 | |
| SCHEMBL10140850 | 0.73 | ALDH1A1 (0.44) | GRM5CNR1IKBKB | |
| SCHEMBL11971249 | 0.73 | SMN1; SMN2 (0.43) | GRM5CNR1 | |
| SCHEMBL18355613 | 0.72 | GRM5 (0.53) | GRM5CNR1 | |
| SCHEMBL14996540 | 0.72 | L3MBTL1 (0.44) | GRM5CNR1 | |
| SCHEMBL12907742 | 0.71 | CNR2 (0.69) | CNR1 | |
| SCHEMBL1483029 | 0.71 | CNR1 (0.48) | GRM5CNR1 | |
| SCHEMBL280162 | 0.70 | CSF1R (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | GRM5 4514/4885CNR1 2805/4885IKBKB 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.